Topic: Peripheral arterial disease - Primary Care
Friday, 30 June 2017
The leading UK cardiovascular conference for the whole primary care team. Expert presenters and a down-to-earth approach help health professionals translate the latest evidence into daily practice and optimise patient care. Participants also receive 9 hours CPD credits. Book now to attend this inspirational event and take advantage of our Early Bird discount.
Sunday, 12 March 2017
A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.
Friday, 19 May 2017
The direct factor Xa inhibitor rivaroxaban has been showing promise in trials in venous thromboembolism (VTE) and peripheral arterial disease (PAD). We provide details from the EINSTEIN CHOICE and COMPASS trials.
Thursday, 16 August 2018
A large, multicentre randomised control trial comparing combination low-dose rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily) in people with stable peripheral arterial disease (PAD) or carotid artery disease (CAD) showed that combination therapy reduced the composite primary outcome of cardiovascular death, stroke or myocardial infarction and increased the risk of major bleeds compared with aspirin (100 mg once daily) alone.